Salarius Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2019
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2016 - 2019
Revenue	-	-	-	-	1.84	5.23	Upgrade
Revenue Growth (YoY)	-	-	-	-	-64.84%	51.03%	Upgrade
Cost of Revenue	-	-	-	-	8.55	6.91	Upgrade
Gross Profit	-	-	-	-	-6.71	-1.68	Upgrade
Selling, General & Admin	5.17	4.96	5.72	7.14	6.1	6.11	Upgrade
Research & Development	0.5	0.77	7.17	15.84	-	-	Upgrade
Operating Expenses	5.68	5.73	12.89	22.98	6.1	6.11	Upgrade
Operating Income	-5.68	-5.73	-12.89	-22.98	-12.81	-7.79	Upgrade
Interest & Investment Income	0.08	0.16	0.35	0.22	-	-	Upgrade
Other Non Operating Income (Expenses)	-	-	-	0.01	0.04	0.43	Upgrade
EBT Excluding Unusual Items	-5.6	-5.58	-12.54	-22.74	-12.77	-7.35	Upgrade
Impairment of Goodwill	-	-	-	-8.87	-	-	Upgrade
Pretax Income	-5.1	-5.58	-12.54	-31.61	-12.77	-7.35	Upgrade
Net Income	-5.1	-5.58	-12.54	-31.61	-12.77	-7.35	Upgrade
Preferred Dividends & Other Adjustments	-	-	-	-	-	0.4	Upgrade
Net Income to Common	-5.1	-5.58	-12.54	-31.61	-12.77	-7.75	Upgrade
Free Cash Flow	-4.14	-4.53	-12.85	-17.6	-10.2	-10.31	Upgrade
Gross Margin	-	-	-	-	-	-32.11%	Upgrade
Operating Margin	-	-	-	-	-696.27%	-148.78%	Upgrade
Profit Margin	-	-	-	-	-693.84%	-148.06%	Upgrade
Free Cash Flow Margin	-	-	-	-	-554.29%	-197.08%	Upgrade
EBITDA	-5.68	-5.73	-12.88	-22.97	-12.79	-7.77	Upgrade
EBITDA Margin	-	-	-	-	-	-148.44%	Upgrade
D&A For EBITDA	0	0	0.01	0.01	0.02	0.02	Upgrade
EBIT	-5.68	-5.73	-12.89	-22.98	-12.81	-7.79	Upgrade
EBIT Margin	-	-	-	-	-	-148.78%	Upgrade

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q